Halaven

Halaven is a brand name of eribulin, approved by the FDA in the following formulation(s):

HALAVEN (eribulin mesylate - solution; intravenous)

• 
  Manufacturer: EISAI INC
  
  Approval date: November 15, 2010
  
  Strength(s): 1MG/2ML (0.5MG/ML) ^[RLD]

Has a generic version of Halaven been approved?

No. There is currently no therapeutically equivalent version of Halaven available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Halaven. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Macrocyclic analogs and methods of their use and preparation
  Patent 6,214,865
  Issued: April 10, 2001
  Inventor(s): Littlefield; Bruce A. & Palme; Monica H. & Seletsky; Boris M. & Towle; Murray J. & Yu; Melvin J. & Zheng; Wanjun
  Assignee(s): Eisai Co., Ltd.
  The invention provides halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity, and methods of identifying agents that induce a sustained mitotic block in a cell after transient exposure of the cell to the agents.
  
  Patent expiration dates:
  
  
  • June 16, 2019
    
    ✓ 
    Drug substance
  
  



• 
  Intermediates in the preparation of macrocyclic analogs
  Patent 6,469,182
  Issued: October 22, 2002
  Inventor(s): Bruce A.; Littlefield & Monica H.; Palme & Boris M.; Seletsky & Murray J.; Towle & Melvin J.; Yu & Wanjun; Zheng
  Assignee(s): Eisai Co., Ltd.
  Novel intermediates of the formula They are used in the preparation of macrocyclic analogs.
  
  Patent expiration dates:
  
  
  • June 16, 2019
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
  
  



• 
  Methods and compositions for use in treating cancer
  Patent 7,470,720
  Issued: December 30, 2008
  Inventor(s): Littlefield; Bruce A. & Towle; Murray J.
  Assignee(s): Eisai R&D Management Co., Ltd.
  The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
  
  Patent expiration dates:
  
  
  • June 16, 2019
    
    ✓ 
    Drug product
  
  



• 
  Methods and compositions for use in treating cancer
  Patent 8,097,648
  Issued: January 17, 2012
  Inventor(s): Littlefield; Bruce A. & Towle; Murray J. & Seletsky; Boris M. & Yu; Melvin J. & Zheng; Wanjun
  Assignee(s): Eisai R&D Management Co., Ltd.
  The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
  
  Patent expiration dates:
  
  
  • January 22, 2021
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 15, 2015 - NEW CHEMICAL ENTITY
  
  

See also...

• Halaven Consumer Information (Drugs.com)
• Halaven Consumer Information (Wolters Kluwer)
• Halaven Consumer Information (Cerner Multum)
• Halaven Advanced Consumer Information (Micromedex)
• Eribulin Consumer Information (Wolters Kluwer)
• Eribulin Consumer Information (Cerner Multum)
• Eribulin Intravenous Advanced Consumer Information (Micromedex)